The controversy over the diabetes drug rosiglitazone (Avandia; GlaxoSmithKline), a peroxisome proliferator-activated receptor-γ agonist, has undermined confidence in developing drugs that target this family of nuclear receptors, but some companies still see promise in the field.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
Scientific Reports Open Access 31 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 9, 668–669 (2010). https://doi.org/10.1038/nrd3271
Issue Date:
DOI: https://doi.org/10.1038/nrd3271
This article is cited by
-
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
Scientific Reports (2017)
-
Structural exploration of PPARγ modulators through pharmacophore mapping, fragment-based design, docking, and molecular dynamics simulation analyses
Medicinal Chemistry Research (2017)
-
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Endocrine (2013)
-
Portfolio Decisions in Early Development
Pharmaceutical Medicine (2012)
-
Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity
Journal of Computer-Aided Molecular Design (2011)